cidofovir anhydrous has been researched along with zalcitabine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Huang, B; Kang, D; Liu, X; Naesens, L; Zhan, P; Zhang, H; Zhou, Z | 1 |
| Andrei, G; Pertusati, F; Pileggi, E; Schols, D; Serpi, M; Snoeck, R | 1 |
| Claessens, F; Dehaen, W; Helsen, C; Karypidou, K; Pannecouque, C; Persoons, L; Quevedo, MA; Ribone, SR | 1 |
| Andrei, G; Cazin, I; Harej, A; Klobučar, M; Macan, AM; Pavelić, K; Pavelić, SK; Raić-Malić, S; Schols, D; Snoeck, R; Stepanić, V | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Allen, SJ; Chen, MS; Cherrington, JM; McKee, BH | 1 |
| Fujiwara, T; Kaneko, H; Mori, S; Shigeta, S | 1 |
| Aoki, K; Kaneko, H; Mori, S; Ohno, S; Shigeta, S | 1 |
| Gordon, YJ; Romanowski, EG; Yates, KA | 1 |
1 review(s) available for cidofovir anhydrous and zalcitabine
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
16 other study(ies) available for cidofovir anhydrous and zalcitabine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via 'privileged scaffold' refining approach.
Topics: Adenoviridae; Antiviral Agents; Carbon-13 Magnetic Resonance Spectroscopy; Cell Line; Drug Discovery; Humans; Mass Spectrometry; Molecular Structure; Proton Magnetic Resonance Spectroscopy; Quinazolines; Structure-Activity Relationship; Vaccinia virus | 2016 |
Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
Topics: Antiviral Agents; Cell Line; DNA Viruses; Drug Stability; Humans; Nucleosides; Organophosphonates; Prodrugs; RNA Viruses; Structure-Activity Relationship | 2018 |
Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents.
Topics: Antiviral Agents; Catalytic Domain; Cell Line, Tumor; Coronavirus; Coronavirus 3C Proteases; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Protein Binding; Structure-Activity Relationship; Triazoles; Viral Proteins | 2018 |
Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Ascorbic Acid; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Triazoles; Viruses | 2019 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases beta and gamma.
Topics: Antiviral Agents; Arabinofuranosyluracil; Cidofovir; Cytosine; Dideoxynucleotides; DNA Polymerase I; DNA Polymerase III; Herpesvirus 1, Human; Herpesvirus 2, Human; Humans; Kinetics; Nucleic Acid Synthesis Inhibitors; Organophosphonates; Organophosphorus Compounds; Thymine Nucleotides; Zalcitabine; Zidovudine | 1994 |
[Evaluation of antiviral agents for adenovirus using the MTT method in vitro].
Topics: Acyclovir; Adenoviridae; Antiviral Agents; Cells, Cultured; Cidofovir; Cytosine; Drug Evaluation, Preclinical; Foscarnet; Humans; Organophosphonates; Organophosphorus Compounds; Zalcitabine | 2000 |
[Antiviral effect of sulfated sialyl lipid against a clinical strain of adenovirus].
Topics: Adenoviridae; Antiviral Agents; Cells, Cultured; Cidofovir; Cytosine; Humans; Lipids; N-Acetylneuraminic Acid; Organophosphonates; Organophosphorus Compounds; Zalcitabine | 2003 |
The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections.
Topics: Adenoviridae Infections; Adenoviruses, Human; Administration, Topical; Animals; Antiviral Agents; Cidofovir; Conjunctivitis, Viral; Cytosine; Disease Models, Animal; Female; Humans; Organophosphonates; Rabbits; Tumor Cells, Cultured; Viral Plaque Assay; Virus Replication; Zalcitabine | 2009 |